Catechol-O-methyltransferase (COMT) inhibitors may be useful in the treatment of Parkinson's disease by improving the bioavailability of levodopa and by prolonging its effects. Entacapone (OR-611), a novel COMT inhibitor, which does not cross the blood brain barrier, was assessed in 12 patients with Parkinson's disease and motor fluctuations in a randomised, double-blind, cross-over, single dose study. The magnitude and duration of the therapeutic response to a single dose of 200 mg levodopa/50 mg carbidopa was evaluated after concomitant placebo, or 200 or 800 mg entacapone. A significant increase in the duration of the motor response to levodopa was seen when 200 mg entacapone was given with levodopa/carbidopa. Plasma levodopa concentrations were increased with both doses of the COMT inhibitor. The latency to onset of motor response did not differ significantly between active drug and placebo. Entacapone may prove useful in prolonging the duration of the benefit obtained from individual doses of levodopa.
central nervous system it is believed to exert its major action in the synaptic cleft.
When decarboxylation of levodopa is blocked by peripheral dopa decarboxylase inhibitors (DCIs), 0-methylation becomes the most prominent pathway of levodopa catabolism2 and leads to the accumulation of 3-0-methyldopa. It has been suggested that 3-0-methyldopa may impair the transport of levodopa across the blood brain barrier and compete with levodopa for decarboxylation within the brain.'-5 It has also been proposed that accumulation of 3-0-methyldopa may be a causal factor in the development of motor fluctuations in Parkinson's disease. 6 This theory, however, has been challenged. The plasma concentrations of 3-0-methyldopa causing a deleterious effect on the clinical response to levodopa in parkinsonian patients are much higher than those found during long term levodopa decarboxylase inhibitor treatment.7-'0 The oral bioavailability of levodopa is low due to first pass metabolism which is at least partly due to the high activity of COMT in the gut and liver." 12 The combination of a peripheral COMT inhibitor with levodopa/DCI therapy might therefore produce a smoother and more prolonged motor response in patients with Parkinson's disease."3 14 As early as in 1971 Ericsson'5 reported beneficial effects with a COMT inhibitor with concomitant reduction in levodopa-induced dyskinesias. More recently, a new generation of COMT inhibitors have been developed, which are much more potent and specific."'3 1620 Fluorodopa positron emission tomography (PET) studies in monkeys and patients with Parkinson's disease have also shown that peripheral COMT inhibitors increase striatal fluorodopa uptake. [21] [22] [23] Entacapone (OR-611) is a highly selective and potent nitrocatechol-structured COMT inhibitor that penetrates the brain poorly, acting mainly in the gut. In animal models of Parkinson's disease, entacapone potentiated and prolonged the therapeutic effect of levodopa in a dose-dependent manner. 2425 We have studied the motor response and pharmacokinetics of levodopa in 12 Entacapone significantly delayed the fall in plasma levodopa concentrations (p < 0 05). The higher dose also delayed the attainment of peak plasma levodopa concentrations but neither 200 nor 800 mg entacapone increased the magnitude of the levodopa peak (fig 2a) . The plasma dihydroxyphenyl acetic acid concentrations were significantly increased and the homovanillic acid concentrations reduced (p < 0-01) with 800 mg of entacapane, but not with 200 mg (fig 2b) . Plasma 3-0-methyldopa concentrations were not significantly different during the three days of the trial. II group.bmj.com on October 8, 2016 -Published by http://jnnp.bmj.com/ Downloaded from concentrations correlated closely. No difference in peak plasma concentrations of levodopa were found between placebo and entacapone, but the slopes of the curves were more gradual and at four hours after giving levodopa plasma concentrations were significantly higher with 200 and 800 mg of entacapone. This is in accordance with results in animals and healthy volunteers. 5 The delay in the attainment of peak plasma levodopa concentrations with 800 mg entacapone might be explained by interference with levodopa absorption in the gut.
The two patients who failed to "switch on" with placebo or 800 mg entacapone normally took 500 mg levodopa in the morning instead of the standard 200 mg dose used in this study. The fact that 200 mg entacapone with 200 mg levodopa "switched them on" might indicate possible levodopa sparing effects. Both patients had very high 3-0-methyldopa concentrations.
The lower concentrations of the 0-methylated and deaminated catabolite of dopamine, homovanillic acid, on both entacapone days and the increased production of the deaminated metabolite, dihydroxyphenyl acetic acid, provide confirmatory evidence that entacapone systematically reduces COMT activity. The finding that these effects were greater with 800 than with 200 mg entacapone implies that COMT inhibition was dose related, even if the improvement in motor response to levodopa was not.
The plasma concentrations of 3-0-methyldopa in patients on chronic levodopa DCI therapy are very high and the half life of 3-0-methyldopa is long (15-16 hours) compared with levodopa (one hour).2 Therefore plasma concentrations of 3-0-methyldopa should not be reduced by a single dose of entacapone. To reduce the plasma concentrations of 3-0-methyldopa chronic COMT inhibition would be required.
